Immuno-oncology programs
GPCRs constitute strategic targets mediating immunosuppression. The company exploits its expertise in the field to move forward small molecule and antibody based-assets toward the clinic.
Immuno-oncology
M1069
A2aR/A2bR antagonist
DT-9081
EP4 receptor antagonist
DT-7012
Anti-CCR8 antibody
DT-9045
PAR2 antagonist
Undisclosed GPCR targets